Global Innovative Platforms (GIPL) Receivables (2026)
Global Innovative Platforms' (GIPL) quarterly Receivables came in at $14700.0 in Q2 2026, down 18.33% quarter-over-quarter from $18000.0 in Q1 2026.
Powered by 
Analysis
Global Innovative Platforms (GIPL) Receivables (2026) Analysis & Trends
Global Innovative Platforms has disclosed Receivables across 1 years of filings, most recently posting $14700.0 for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 42.23 Bn | 42.03 Bn | 779.09 Mn | 709.36 Mn |
| 2 | Zoetis | 31.39 Bn | 29.72 Bn | 1.05 Bn | 1.57 Bn |
| 3 | Elanco Animal Health | 12.21 Bn | 11.68 Bn | 798.00 Mn | 1.15 Bn |
| 4 | Phibro Animal Health | 1.55 Bn | 1.47 Bn | 134.40 Mn | 252.66 Mn |
| 5 | Immucell | 89.91 Mn | 81.05 Mn | 2.44 Mn | 2.90 Mn |
| 6 | Zhengye Biotechnology Holding | 76.30 Mn | 77.22 Mn | - | 5.25 Mn |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | 14,700.00 |